Compare CYBN & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYBN | IGD |
|---|---|---|
| Founded | 2019 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.1M | 449.6M |
| IPO Year | N/A | N/A |
| Metric | CYBN | IGD |
|---|---|---|
| Price | $8.28 | $5.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $74.50 | N/A |
| AVG Volume (30 Days) | ★ 916.5K | 215.3K |
| Earning Date | 02-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.15% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.81 | $4.60 |
| 52 Week High | $10.73 | $5.26 |
| Indicator | CYBN | IGD |
|---|---|---|
| Relative Strength Index (RSI) | 68.97 | 40.67 |
| Support Level | $7.85 | $5.66 |
| Resistance Level | $9.12 | $5.88 |
| Average True Range (ATR) | 0.51 | 0.05 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 68.59 | 19.54 |
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.